Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.52 |
| ▸ | BRD2 | P25440 | 11/20 | 0.52 |
| ▸ | BRD3 | Q15059 | 10/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723155 | 1.00 | BRD4 (0.52) | BRD4BRD2BRD3SMN1; SMN2NR3C1 | |
| SCHEMBL15437155 | 0.84 | BRD4 (0.57) | BRD4BRD2BRD3 | |
| SCHEMBL13724313 | 0.84 | BRD4 (0.57) | BRD4BRD2BRD3 | |
| SCHEMBL15450340 | 0.84 | HRH3 (0.49) | BRD4BRD2BRD3SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL15437438 | 0.83 | HRH3 (0.49) | BRD4BRD2BRD3SMN1; SMN2 | |
| SCHEMBL13723722 | 0.82 | BRD4 (0.59) | BRD4BRD2BRD3 | |
| SCHEMBL13724410 | 0.82 | BRD4 (0.54) | BRD4BRD2BRD3 | |
| SCHEMBL15437286 | 0.82 | BRD4 (0.54) | BRD4BRD2BRD3 | |
| SCHEMBL13724323 | 0.82 | BRD4 (0.63) | BRD4BRD2BRD3 | |
| SCHEMBL15437262 | 0.82 | BRD4 (0.49) | BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3168213-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-3168213-A1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | Glaxosmithkline LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| EP-2699551-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2699551-B1 | TETRAHYDROQUINOLINE DERIVATIVES USEFUL AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8993554-B2 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993554-B2 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993554-B2 | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | GLAXOSMITHKLINE LLC (US) | 2014-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031336-A1 | Tetrahydroquinoline Derivatives Useful As Bromodomain Inhibitors | BRD4, BRDT, BRD3 | BRD4 1/4885BRD2 4/4885BRD3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.